- Home
- AFRI vs MRSN Comparison
AFRI vs MRSN Comparison
Compare AFRI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- MRSN
- Stock Information
- Founded
- AFRI 1943
- MRSN 2001
- Country
- AFRI Gibraltar
- MRSN United States
- Employees
- AFRI N/A
- MRSN N/A
- Industry
- AFRI Packaged Foods
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- MRSN Health Care
- Exchange
- AFRI Nasdaq
- MRSN Nasdaq
- Market Cap
- AFRI 275.5M
- MRSN 252.0M
- IPO Year
- AFRI N/A
- MRSN 2017
- Fundamental
- Price
- AFRI $10.06
- MRSN $1.36
- Analyst Decision
- AFRI
- MRSN Buy
- Analyst Count
- AFRI 0
- MRSN 6
- Target Price
- AFRI N/A
- MRSN $6.00
- AVG Volume (30 Days)
- AFRI 10.7K
- MRSN 1.6M
- Earning Date
- AFRI 01-14-2025
- MRSN 02-26-2025
- Dividend Yield
- AFRI N/A
- MRSN N/A
- EPS Growth
- AFRI N/A
- MRSN N/A
- EPS
- AFRI N/A
- MRSN N/A
- Revenue
- AFRI $305,476,000.00
- MRSN $34,837,000.00
- Revenue This Year
- AFRI N/A
- MRSN N/A
- Revenue Next Year
- AFRI N/A
- MRSN N/A
- P/E Ratio
- AFRI N/A
- MRSN N/A
- Revenue Growth
- AFRI 5.42
- MRSN N/A
- 52 Week Low
- AFRI $9.63
- MRSN $1.22
- 52 Week High
- AFRI $12.00
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- AFRI 45.28
- MRSN 32.49
- Support Level
- AFRI $10.01
- MRSN $1.38
- Resistance Level
- AFRI $10.36
- MRSN $1.52
- Average True Range (ATR)
- AFRI 0.28
- MRSN 0.18
- MACD
- AFRI -0.00
- MRSN -0.04
- Stochastic Oscillator
- AFRI 27.37
- MRSN 12.00
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.